企業プロフィール
Anebulo Pharmaceuticals 株価・ニュース・カタリスト
- ティッカー:
- ANEB
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
0.33 USD (-5.69%)
終値
最終更新: 2026年8月21日
—
時価総額
株価変動の要因
Current closing-price context is not available for ANEB.
企業概要
Cannabis-Toxicity Antidote
Anebulo Pharmaceuticals develops a specific treatment for acute cannabis-induced toxicity in adults and children. The company’s approach directly blocks the cannabinoid receptor responsible for many central effects of THC.
Selonabant
Selonabant, or ANEB-001, is a small-molecule CB1 receptor antagonist. Oral selonabant blocked or reversed key THC effects in a controlled Phase 2 proof-of-concept study in healthy adults.
Pediatric Intravenous Strategy
Anebulo is prioritizing an intravenous formulation for pediatric cannabis poisoning rather than moving the adult oral product directly into Phase 3. The company has scaled the IV formulation and initiated a Phase 1 single-ascending-dose safety study.
今後のカタリスト
- Anebulo's story is now centered on selonabant and the company's decision to step away from Nasdaq. That makes the next chapter feel more like a value-maximization exercise around a finished Phase 2 asset than a broad public-development story.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。